Novavax (NVAX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

Novavax, Inc. (Nasdaq: NVAX) today announced its financial results and operational highlights for the second quarter ended ...

The move would add another barrier for parents who want to vaccinate healthy children ahead of the respiratory virus season.

Shares of the biotech were up 4.3% in premarket trading, after it also beat Wall Street expectations for second-quarter ...

Novavax (NVAX) stock gains as the company beats Q2 revenue estimates and raises its 2025 revenue outlook, buoyed by ...

(Reuters) -Novavax beat Wall Street expectations for second-quarter revenue on Wednesday, helped by a $175 million milestone ...

Novavax posted a surprise profit in Q2 2025, reporting GAAP EPS of $0.62 compared to an expected loss of $0.04 per share. Revenue (GAAP) was $239 million, well above the analyst estimate of $152.61 ...

Novavax was a rags-to-riches story early in the pandemic when it scored a $1.6 billion grant from the government to develop a COVID-19 vaccine.

Shares of COVID-19 vaccine maker Novavax cratered Tuesday as the U.S. biotech company slashed its sales forecast due to a slump in demand for its shots. The company's stock dived 31% after it cut ...

Novavax says its Covid-19 vaccine is 90 percent effective overall and 100 percent effective against severe disease. If authorized by the FDA, it would be the country's fourth vaccine.

Key Points Novavax's COVID-19 vaccine could prove to be highly effective against the delta variant. The most likely path to success for Novavax's vaccine in the U.S. market is as a booster shot.